journal article·2022

Recent advances in nanotechnology approaches for non-viral gene therapy

Yihang Jiang, Miaozhuang Fan, Zhenxu Yang, Xiaochen Liu, Zhourui Xu, Shikang Liu, Gang Feng, Shuo Tang, Zhengzheng Li, Yibin Zhang, Shilin Chen, Chengbin Yang, Wing-Cheung Law, Biqin Dong, Gaixia Xu, Ken-Tye Yong

Biomaterials Science· Volume 10· Issue 24
Publisher page

Abstract

Gene therapy has shown great potential in the treatment of many diseases by downregulating the expression of certain genes. The development of gene vectors as a vehicle for gene therapy has greatly facilitated the widespread clinical application of nucleic acid materials (DNA, mRNA, siRNA, and miRNA). Currently, both viral and non-viral vectors are used as delivery systems of nucleic acid materials for gene therapy. However, viral vector-based gene therapy has several limitations, including immunogenicity and carcinogenesis caused by the exogenous viral vectors. To address these issues, non-viral nanocarrier-based gene therapy has been explored for superior performance with enhanced gene stability, high treatment efficiency, improved tumor-targeting, and better biocompatibility. In this review, we discuss various non-viral vector-mediated gene therapy approaches using multifunctional biodegradable or non-biodegradable nanocarriers, including polymer-based nanoparticles, lipid-based nanoparticles, carbon nanotubes, gold nanoparticles (AuNPs), quantum dots (QDs), silica nanoparticles, metal-based nanoparticles and two-dimensional nanocarriers. Various strategies to construct non-viral nanocarriers based on their delivery efficiency of targeted genes will be introduced. Subsequently, we discuss the cellular uptake pathways of non-viral nanocarriers. In addition, multifunctional gene therapy based on non-viral nanocarriers is summarized, in which the gene therapy can be combined with other treatments, such as photothermal therapy (PTT), photodynamic therapy (PDT), immunotherapy and chemotherapy. We also provide a comprehensive discussion of the biological toxicity and safety of non-viral vector-based gene therapy. Finally, the present limitations and challenges of non-viral nanocarriers for gene therapy in future clinical research are discussed, to promote wider clinical applications of non-viral vector-based gene therapy.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, Guangdong 518055, China

School of Biomedical Engineering, The University of Sydney, Sydney, New South Wales 2006, Australia

The University of Sydney Nano Institute, The University of Sydney, Sydney, New South Wales 2006, Australia

The Biophotonics and Mechanobioengineering Laboratory, The University of Sydney, Sydney, New South Wales 2006, Australia

Department of Industrial and Systems Engineering, The Hong Kong Polytechnic University, Hung Hom, Kowloon 999077, Hong Kong, China

Guangdong Provincial Key Laboratory of Durability for Marine Civil Engineering, College of Civil and Transportation Engineering, Shenzhen University, Shenzhen 518060, China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · Shenzhen University · University of Sydney

References (100+)

Show source-provided references
1. Azzouz · Biochim. Biophys. Acta, Mol. Basis Dis. · 2006 · 1762 · 112210.1016/j.bbadis.2006.05.003 ↗
2. Brannon-Peppas · Adv. Drug Delivery Rev. · 2004 · 56 · 164910.1016/j.addr.2004.02.014 ↗
3. Di Gioia · Pulm. Pharmacol. Ther. · 2015 · 34 · 810.1016/j.pupt.2015.07.003 ↗
4. Quader · Mol. Ther. · 2017 · 25 · 150110.1016/j.ymthe.2017.04.026 ↗
5. Chen · Mol. Ther.–Methods Clin. Dev. · 2016 · 3 · 1602310.1038/mtm.2016.23 ↗
6. Choi · Mol. Cell. Toxicol. · 2014 · 10 · 110.1007/s13273-014-0001-3 ↗
7. S.Nimesh , Gene therapy: Potential applications of nanotechnology , Elsevier , 201310.1533/9781908818645 ↗
8. Ramamoorth · J. Clin. Diagn. Res. · 2015 · 9 · GE01
9. Xu · J. Biomed. Nanotechnol. · 2014 · 10 · 348310.1166/jbn.2014.2044 ↗
10. Li · Gene Ther. · 2000 · 7 · 3110.1038/sj.gt.3301110 ↗
11. Viola · Expert Opin. Drug Delivery · 2010 · 7 · 72110.1517/17425241003716810 ↗
12. Kim · Anal. Bioanal. Chem. · 2010 · 397 · 317310.1007/s00216-010-3821-6 ↗
13. Salimzadeh · Avicenna J. Med. Biotechnol. · 2013 · 5 · 68
14. Yang · Proc. Natl. Acad. Sci. U. S. A. · 1990 · 87 · 956810.1073/pnas.87.24.9568 ↗
15. Van Tendeloo · Curr. Opin. Mol. Ther. · 2007 · 9 · 423
16. Weissman · Mol. Ther. · 2015 · 23 · 141610.1038/mt.2015.138 ↗
17. Park · Int. J. Biol. Sci. · 2021 · 17 · 144610.7150/ijbs.59233 ↗
18. Schoenmaker · Int. J. Pharm. · 2021 · 601 · 12058610.1016/j.ijpharm.2021.120586 ↗
19. Ledley · Hum. Gene Ther. · 1995 · 6 · 112910.1089/hum.1995.6.9-1129 ↗
20. Li · Gene Ther. · 2006 · 13 · 131310.1038/sj.gt.3302838 ↗
21. Niidome · Gene Ther. · 2002 · 9 · 164710.1038/sj.gt.3301923 ↗
22. Keles · Biomater. Sci. · 2016 · 4 · 129110.1039/C6BM00441E ↗
23. Riley · Nanomaterials · 2017 · 7 · 9410.3390/nano7050094 ↗
24. Liu · Biochem. Biophys. Res. Commun. · 2022 · 590 · 16910.1016/j.bbrc.2021.12.089 ↗
25. Loh · Biomater. Sci. · 2016 · 4 · 7010.1039/C5BM00277J ↗
26. Rao · Dalton Trans. · 2007 · 372810.1039/b708342d ↗
27. Hosseinkhani · J. Nanopart. Res. · 2013 · 15 · 179410.1007/s11051-013-1794-z ↗
28. Mahapatro · J. Nanobiotechnol. · 2011 · 9 · 110.1186/1477-3155-9-55 ↗
29. Mokhtarzadeh · Expert Opin. Biol. Ther. · 2016 · 16 · 77110.1517/14712598.2016.1169269 ↗
30. Panyam · Adv. Drug Delivery Rev. · 2003 · 55 · 32910.1016/S0169-409X(02)00228-4 ↗
31. Intra · J. Controlled Release · 2008 · 130 · 12910.1016/j.jconrel.2008.04.014 ↗
32. Wightman · J. Gene Med. · 2001 · 3 · 36210.1002/jgm.187 ↗
33. Lungwitz · Eur. J. Pharm. Biopharm. · 2005 · 60 · 24710.1016/j.ejpb.2004.11.011 ↗
34. Wojnilowicz · ACS Nano · 2019 · 13 · 18710.1021/acsnano.8b05151 ↗
35. Fischer · Pharm. Res. · 1999 · 16 · 127310.1023/A:1014861900478 ↗
36. Karimov · Eur. J. Pharm. Biopharm. · 2021 · 161 · 5610.1016/j.ejpb.2021.02.005 ↗
37. Luo · Biomaterials · 2011 · 32 · 992510.1016/j.biomaterials.2011.09.011 ↗
38. Giger · J. Controlled Release · 2011 · 150 · 8710.1016/j.jconrel.2010.11.012 ↗
39. Guo · Acc. Chem. Res. · 2012 · 45 · 97110.1021/ar200151m ↗
40. Pissuwan · J. Controlled Release · 2011 · 149 · 6510.1016/j.jconrel.2009.12.006 ↗
41. Han · NanoBiotechnology · 2007 · 3 · 4010.1007/s12030-007-0005-3 ↗
42. Ghosh · ACS Nano · 2008 · 2 · 221310.1021/nn800507t ↗
43. Rosi · Science · 2006 · 312 · 102710.1126/science.1125559 ↗
44. Ekin · J. Gene Med. · 2014 · 16 · 33110.1002/jgm.2810 ↗
45. Pankhurst · J. Phys. D: Appl. Phys. · 2003 · 36 · R16710.1088/0022-3727/36/13/201 ↗
46. Bi · Chin. Chem. Lett. · 2020 · 31 · 304110.1016/j.cclet.2020.07.030 ↗
47. Pan · Cancer Res. · 2007 · 67 · 815610.1158/0008-5472.CAN-06-4762 ↗
48. Shubayev · Adv. Drug Delivery Rev. · 2009 · 61 · 46710.1016/j.addr.2009.03.007 ↗
49. Scherer · Gene Ther. · 2002 · 9 · 10210.1038/sj.gt.3301624 ↗
50. McBain · Nanotechnology · 2008 · 19 · 40510210.1088/0957-4484/19/40/405102 ↗
51. Yu · Mol. Ther.–Nucleic Acids · 2016 · 5 · e31810.1038/mtna.2016.28 ↗
52. Zhou · Acta Pharm. Sin. B · 2018 · 8 · 16510.1016/j.apsb.2018.01.007 ↗
53. Bai · J. Mater. Chem. B · 2019 · 7 · 120910.1039/C8TB02946F ↗
54. Chen · Emergent Mater. · 2020 · 3 · 38110.1007/s42247-020-00078-1 ↗
55. Tarn · Acc. Chem. Res. · 2013 · 46 · 79210.1021/ar3000986 ↗
56. Singh · J. Am. Chem. Soc. · 2005 · 127 · 438810.1021/ja0441561 ↗
57. Sayes · Toxicol. Lett. · 2006 · 161 · 13510.1016/j.toxlet.2005.08.011 ↗
58. Chi · J. Hazard. Mater. · 2016 · 318 · 50710.1016/j.jhazmat.2016.07.013 ↗
59. Habibizadeh · Mater. Sci. Eng., C · 2017 · 74 · 110.1016/j.msec.2016.12.023 ↗
60. Reshma · J. Lumin. · 2019 · 205 · 28710.1016/j.jlumin.2018.09.015 ↗
61. Alaghmandfard · Mater. Sci. Eng., C · 2021 · 120 · 11175610.1016/j.msec.2020.111756 ↗
62. Hasanzadeh · J. Drug Delivery Sci. Technol. · 2021 · 61 · 10211810.1016/j.jddst.2020.102118 ↗
63. Riley · Sci. Adv. · 2021 · 7 · eaba102810.1126/sciadv.aba1028 ↗
64. Cruz · Biomaterials · 2021 · 268 · 12058010.1016/j.biomaterials.2020.120580 ↗
65. Wu · Macromol. Biosci. · 2017 · 17 · 170011410.1002/mabi.201700114 ↗
66. Lee · J. Controlled Release · 2021 · 330 · 90710.1016/j.jconrel.2020.10.064 ↗
67. Yang · Bioact. Mater. · 2020 · 5 · 105310.1016/j.bioactmat.2020.07.003 ↗
68. Walsh · N. Engl. J. Med. · 2020 · 383 · 243910.1056/NEJMoa2027906 ↗
69. Jackson · N. Engl. J. Med. · 2020 · 383 · 192010.1056/NEJMoa2022483 ↗
70. Rauch · npj Vaccines · 2021 · 6 · 5710.1038/s41541-021-00311-w ↗
71. Rosenblum · Sci. Adv. · 2020 · 6 · eabc945010.1126/sciadv.abc9450 ↗
72. Li · Bioact. Mater. · 2022 · 9 · 59010.1016/j.bioactmat.2021.05.051 ↗
73. Finn · Cell Rep. · 2018 · 22 · 222710.1016/j.celrep.2018.02.014 ↗
74. Cheng · Nat. Nanotechnol. · 2020 · 15 · 31310.1038/s41565-020-0669-6 ↗
75. Wang · Proc. Natl. Acad. Sci. U. S. A. · 2016 · 113 · 286810.1073/pnas.1520244113 ↗
76. Swingle · J. Controlled Release · 2022 · 341 · 61610.1016/j.jconrel.2021.10.031 ↗
77. Vedadghavami · Nano Today · 2020 · 34 · 10089810.1016/j.nantod.2020.100898 ↗
78. Kavand · J. Controlled Release · 2020 · 321 · 28510.1016/j.jconrel.2020.02.019 ↗
79. Merdan · Adv. Drug Delivery Rev. · 2002 · 54 · 71510.1016/S0169-409X(02)00046-7 ↗
80. Vij · J. Nanobiotechnol. · 2010 · 8 · 2210.1186/1477-3155-8-22 ↗
81. Xing · Biomater. Sci. · 2020 · 8 · 661110.1039/D0BM01222J ↗
82. Malik · J. Controlled Release · 2020 · 327 · 40610.1016/j.jconrel.2020.08.026 ↗
83. Pillai · Pharmaceutics · 2021 · 13 · 142010.3390/pharmaceutics13091420 ↗
84. Byrne · Biomater. Sci. · 2013 · 1 · 122310.1039/c3bm60123d ↗
85. Ahn · J. Controlled Release · 2004 · 97 · 567
86. Akinc · J. Gene Med. · 2005 · 7 · 65710.1002/jgm.696 ↗
87. Benns · Bioconjugate Chem. · 2000 · 11 · 63710.1021/bc0000177 ↗
88. El-Toni · Nanoscale · 2016 · 8 · 251010.1039/C5NR07004J ↗
89. Zhang · J. Controlled Release · 2016 · 229 · 13010.1016/j.jconrel.2016.03.020 ↗
90. Frankel · Cell · 1988 · 55 · 118910.1016/0092-8674(88)90263-2 ↗
91. Morris · Biol. Cell · 2008 · 100 · 20110.1042/BC20070116 ↗
92. Di Martino · Biomaterials · 2005 · 26 · 598310.1016/j.biomaterials.2005.03.016 ↗
93. Kim · Prog. Polym. Sci. · 2007 · 32 · 72610.1016/j.progpolymsci.2007.05.001 ↗
94. Mittal · Eur. Polym. J. · 2018 · 109 · 40210.1016/j.eurpolymj.2018.10.013 ↗
95. Fu · Int. J. Biol. Macromol. · 2017 · 103 · 57510.1016/j.ijbiomac.2017.05.066 ↗
96. Krishnan · Carbohydr. Polym. · 2016 · 151 · 41710.1016/j.carbpol.2016.05.082 ↗
97. Babii · Int. J. Biol. Macromol. · 2020 · 159 · 4610.1016/j.ijbiomac.2020.05.048 ↗
98. Lin · J. Mater. Chem. B · 2017 · 5 · 332710.1039/C6TB03116A ↗
99. Yang · Adv. Healthcare Mater. · 2019 · 8 · 180131810.1002/adhm.201801318 ↗
100. Yang · J. Mater. Chem. B · 2015 · 3 · 216310.1039/C4TB01623H ↗